Hyperglycemia raises the threshold of levosimendan- but not milrinone-induced postconditioning in rat hearts [PDF]
, 2012 Background The authors examined whether milrinone and levosimendan could exert cardiac postconditioning effects in rats under normoglycemia and hyperglycemia, and whether the effects could be mediated by mitochondrial permeability transition pore (mPTP).
Shuhei Matsumoto +6 more
core +2 more sources
Levosimendan in critical illness: A literature review [PDF]
, 2014 Levosimendan, the active enantiomer of simendan, is a calcium sensitizer developed for treatment of decompensated heart failure, exerts its effects independently of the beta adrenergic receptor and seems beneficial in cases of severe, intractable heart ...
Franchi, Federico +5 more
core +2 more sources
Comparison of Levosimendan, Milrinone and Dobutamine in treating Low Cardiac Output Syndrome Following Valve Replacement Surgeries with Cardiopulmonary Bypass [PDF]
Journal of Clinical and Diagnostic Research, 2016 Introduction: Low Cardiac Output Syndrome (LCOS) following Cardiopulmonary Bypass (CPB) is common and associated with increased mortality. Maintenance of adequate cardiac output is one of the primary objectives in management of such patients. Aim: To
Sunny +5 more
doaj +1 more source
JACC. Heart failure, 2021 OBJECTIVES The purpose of this study was to evaluate the effects of intravenous levosimendan on hemodynamics and 6-min walk distance (6MWD) in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF ...
D. Burkhoff +15 more
semanticscholar +1 more source
The importance of pharmacokinetics, pharmacodynamic and repetitive use of levosimendan.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022 Levosimendan was introduced into routine clinical practice in 2000, obtaining approval for the treatment of decompensation of severe chronic heart failure.
G. Grześk +7 more
semanticscholar +1 more source
Le lévosimendan en cardiologie et chirurgie cardiaque sous circulation extracorporelle
Avicenna Medical Research, 2023 Introduction : le lévosimendan est un agent inodilatateur utilisé avec succès dans le traitement de l’insuffisance cardiaque aigue et chronique.
Sayad, M Abdelbaki, Mehyaoui
doaj +1 more source
Use of Levosimendan in Patients with Advanced Heart Failure: An Update
Journal of Clinical Medicine, 2022 Levosimendan is an inodilator drug that, given its unique pharmacological actions and safety profile, represents a viable therapeutic option in patients with heart failure with reduced ejection fraction in the advanced stage of the disease (advHFrEF ...
D. Masarone +8 more
semanticscholar +1 more source
Annals of Translational Medicine, 2022 Background Sepsis is a leading cause of death in China, the mortality rate of which is elevated when cardiac dysfunction is induced. Levosimendan is used for the treatment of decompensated cardiac failure. In this study, we sought to investigate the role
Jian-yong Shi +4 more
semanticscholar +1 more source
Role of calcium desensitization in the treatment of myocardial dysfunction after deep hypothermic circulatory arrest [PDF]
, 2013 Introduction Rewarming from deep hypothermic circulatory arrest (DHCA) produces calcium desensitization by troponin I (cTnI) phosphorylation which results in myocardial dysfunction.
Faggian, Giuseppe +9 more
core +3 more sources
Current state of knowledge on Takotsubo Syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology [PDF]
, 2015 Takotsubo syndrome is an acute reversible heart failure syndrome that is increasingly recognized in modern cardiology practice. This Position Statement from the European Society of Cardiology Heart Failure Association provides a comprehensive review of ...
Akashi, YJ +13 more
core +2 more sources